COPENHAGEN, Denmark, March 7, 2018 /PRNewswire/ -- Veloxis Pharmaceuticals A/S announced today that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food & Drug Administration (FDA) seeking a new indication for ENVARSUS XR (tacrolimus extended-release tablets)...